Trials / Completed
CompletedNCT03541694
Passive Enhanced Safety Surveillance of Stamaril® Vaccine in Korea
Passive Enhanced Safety Surveillance of the Live Attenuated Yellow Fever Virus Vaccine Stamaril® in Korea
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 622 (actual)
- Sponsor
- Sanofi Pasteur, a Sanofi Company · Industry
- Sex
- All
- Age
- —
- Healthy volunteers
- Accepted
Summary
This is a passive enhance safety surveillance (ESS) of Stamaril® vaccine in Korea. The objective is to collect suspected related adverse events following vaccination with Stamaril® in routine practice.
Detailed description
This ESS replaces the routing post-marketing surveillance required after product approval in Korea.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Stamaril® | Routine vaccination with Stamaril yellow fever vaccine |
Timeline
- Start date
- 2018-04-11
- Primary completion
- 2018-05-30
- Completion
- 2018-05-30
- First posted
- 2018-05-30
- Last updated
- 2019-03-26
Locations
1 site across 1 country: South Korea
Source: ClinicalTrials.gov record NCT03541694. Inclusion in this directory is not an endorsement.